CABA

Cabaletta BioB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$6.00

+63.0% vs current

Most likely

Base case

45%

Probability

Target price

$3.60

-2.2% vs current

B-

Bear case

30%

Probability

Target price

$1.60

-56.5% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

CABA remains a cautious monitoring name rather than a clean momentum long: the company has real primary-source-defined catalysts, and the peer frame is better anchored by KYTX and RNAC than by generic small-cap biotech comps, but the deterministic prior is still neutral and forward visibility remains dominated by milestone and funding risk.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-06-30event1H26 multi-program clinical data dropHigh impact

Management said on March 23, 2026 that complete Phase 1/2 data from RESET-SSc, RESET-SLE and RESET-MG are expected in 1H26, with no-preconditioning SLE data also on deck; this is the cleanest near-term proof point for whether rese-cel can support broader registrational planning beyond myositis [#8-K-2026-03-23] [#PR-2026-03-23].

2026-06-30catalystAutomated manufacturing readiness on Cellares platformHigh impact

Cabaletta's January 12, 2026 strategic priorities update said automated Cellares manufacturing had IND-amendment clearance and that clinical manufacturing data were expected in 1H26 to confirm GMP readiness and logistics; if credible, this could improve the scale and margin narrative, but execution remains early [#PR-2026-01-12].

2026-12-31catalystMyositis registrational cohort progress toward planned 2027 BLAHigh impact

The company says the 17-patient registrational myositis cohort is enrolling and remains the lead path to a planned 2027 BLA, including an outpatient dosing option; steady enrollment and clean updates through 2026 would support the lead asset, while slippage would undermine the core thesis [#PR-2026-01-12] [#PR-2026-03-23].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology